Journal: Molecular Medicine Reports

Article Title: Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium

doi: 10.3892/mmr.2020.11745

Figure Lengend Snippet: Detection of MUC5AC expression in normal bile duct tissue and in tissues from patients with hepatoliths. (A) Immunohistochemistry assay of MUC5AC staining in paraffin-embedded sections from normal human subjects and patients with hepatoliths at different magnifications and quantitative analysis of MUC5AC expression level of each section. (B) Co-staining immunofluorescence experiments for MUC5AC and Sp1 expression in sections from normal human subjects and patients with hepatoliths (magnification, ×400), with quantitative analysis of Sp1 expression levels in each section. (C) Reverse transcription-quantitative PCR experiments for miR-130b expression in clinical tissue from normal human subjects and patients with hepatoliths. n=8 in the control group; n=10 in the hepatolith group. **P<0.01. MUC5AC, mucin 5AC; Sp1, specificity protein 1; miR, micro130b RNA.

Article Snippet: Subsequently, 250 μl concentrated cell supernatant solution was obtained from the control, LPS exposure, Sp1 shRNA transfection and miR130b mimics intervention groups and assayed using the human MUC5AC ELISA assay kit (cat. no. CSB-E10109h; Cusabio Technology, LLC) to determine MU5AC concentration.

Techniques: Expressing, Immunohistochemistry, Staining, Immunofluorescence, Reverse Transcription, Real-time Polymerase Chain Reaction, Control

Journal: Molecular Medicine Reports

Article Title: Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium

doi: 10.3892/mmr.2020.11745

Figure Lengend Snippet: Detection of miR-130b, Sp1 and MUC5AC expression in HIBEpiCs following LPS treatment. (A) ELISA was performed to detect changes in MUC5AC expression in HIBEpiC supernatant. (B) RT-qPCR was performed to detect changes in MUC5AC and Sp1 mRNA expression in HIBEpiCs. (C) Western blotting was performed to detect changes Sp1 protein expression in HIBEpiCs. (D) RT-qPCR was performed to detect changes in miR-130b expression in HIBEpiCs. (E) immunofluorescence experiments for HIBEpiCs were performed to detect the transmembrane location of Sp1 in the control group compared with the 10 µg/ml LPS treatment group. Magnification, ×40. *P<0.05, **P<0.01. MUC5AC, mucin 5AC; Sp1, specificity protein 1; miR, microRNA; HIBEpiCs, human intrahepatic biliary epithelial cells; LPS, lipopolysaccharide; RT-qPCR, reverse transcription-quantitative PCR.

Article Snippet: Subsequently, 250 μl concentrated cell supernatant solution was obtained from the control, LPS exposure, Sp1 shRNA transfection and miR130b mimics intervention groups and assayed using the human MUC5AC ELISA assay kit (cat. no. CSB-E10109h; Cusabio Technology, LLC) to determine MU5AC concentration.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Western Blot, Immunofluorescence, Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Molecular Medicine Reports

Article Title: Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium

doi: 10.3892/mmr.2020.11745

Figure Lengend Snippet: MUC5AC, Sp1 and miR-130b levels in an intrahepatic bile duct stone animal model. (A) Sprague-Dawley rats underwent laparotomy and a PE tube was inserted into their common bile duct and fixed. The PE tube was placed from the back of the neck through a subcutaneous tunnel and fixed. (B) Days of each drug injection. (C) Rat serum levels of AST, ALT and TB were measured. (D) Images of rat bile smears after modeling. (E) Western blotting was performed to measure Sp1 expression in bile duct tissues from different groups. (F) RT-qPCR assay to detect expression of miR-130b in bile duct tissues across different groups. (G) RT-qPCR assay to detect expression levels of Sp1 and MUC5AC in bile duct tissues from different groups. (H) Correlation analysis of Sp1 and miR-130b mRNA expression levels. (I) Correlation analysis of MUC5AC and Sp1 mRNA expression levels. *P<0.05, **P<0.01 and ***P<0.0001. AST, aspartate transaminase; ALT, alanine aminotransferase; TB, total bilirubin; MUC5AC, mucin 5AC; Sp1, specificity protein 1; miR, microRNA; RT-qPCR, reverse transcription-quantitative PCR; PE, polyethylene.

Article Snippet: Subsequently, 250 μl concentrated cell supernatant solution was obtained from the control, LPS exposure, Sp1 shRNA transfection and miR130b mimics intervention groups and assayed using the human MUC5AC ELISA assay kit (cat. no. CSB-E10109h; Cusabio Technology, LLC) to determine MU5AC concentration.

Techniques: Animal Model, Injection, Western Blot, Expressing, Quantitative RT-PCR, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Molecular Medicine Reports

Article Title: Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium

doi: 10.3892/mmr.2020.11745

Figure Lengend Snippet: Identifying the direct binding position of Sp1 to the MUC5AC promoter sequence and further verification of the regulatory effect of Sp1 by transfection. (A) An online database was used to predict the possible binding positions for Sp1 to the MUC5AC promoter sequence. (B) Chromatin immunoprecipitation-qPCR experiments showing the Sp1 binding site on the MUC5AC promoter sequence and the alterations of Sp1 binding intensity between control and experimental groups (10 µg/ml LPS pretreatment for 24 h). HIBEpiCs were transfected with shRNA to overexpress Sp1 or shRNA to inhibit Sp1 or pretreated with 10 µg/ml mithramycin A (an Sp1 inhibitor). (C) RT-qPCR detection of Sp1 mRNA expression in HIBEpiCs. (D) Western blotting assay of Sp1 protein expression in HIBEpiCs. (E) RT-qPCR detection of MUC5AC mRNA expression in HIBEpiCs. (F) ELISA detection of MUC5AC expression in HIBEpiC supernatant. *P<0.05, **P<0.01 and ***P<0.0001. MUC5AC, mucin 5AC; Sp1, specificity protein 1; HIBEpiCs, human intrahepatic biliary epithelial cells; LPS, lipopolysaccharide; RT-qPCR, reverse transcription-quantitative PCR; shRNA, short hairpin RNA; NC, negative control; MA, mithramycin A.

Article Snippet: Subsequently, 250 μl concentrated cell supernatant solution was obtained from the control, LPS exposure, Sp1 shRNA transfection and miR130b mimics intervention groups and assayed using the human MUC5AC ELISA assay kit (cat. no. CSB-E10109h; Cusabio Technology, LLC) to determine MU5AC concentration.

Techniques: Binding Assay, Sequencing, Transfection, Chromatin Immunoprecipitation, Control, shRNA, Quantitative RT-PCR, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Reverse Transcription, Real-time Polymerase Chain Reaction, Negative Control

Journal: Molecular Medicine Reports

Article Title: Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium

doi: 10.3892/mmr.2020.11745

Figure Lengend Snippet: Investigation of the direct binding position between miR-130b and the 3′-UTR sequence of Sp1 and further verification of the regulatory effect of miR-130b on MUC5AC and Sp1 expression. (A) Online tools were used to predict the binding position of miR-130b to the 3′-UTR sequence of Sp1, and the corresponding luciferase primer for a natural plasmid and a mutated plasmid were established. (B and C) Luciferase gene detection for miR-130b and the Sp1 3′-UTR sequence. HIBEpiCs were transfected with miR-130b overexpression mimics or miR-130b inhibitors for 24 h. (D) RT-qPCR detected changes in miR-130b expression in HIBEpiCs. (E) RT-qPCR detected changes in of Sp1 mRNA expression in HIBEpiCs. (F) Western blotting detected changes Sp1 protein expression in HIBEpiCs. (G) RT-qPCR detected changes in of MUC5AC mRNA expression in HIBEpiCs. (H) ELISA detected changes in MUC5AC levels in HIBEpiC supernatant. *P<0.05, **P<0.01 and ***P<0.0001. MUC5AC, mucin 5AC; Sp1, specificity protein 1; miR, microRNA; HIBEpiCs, human intrahepatic biliary epithelial cells; RT-qPCR, reverse transcription-quantitative PCR; 3′-UTR, 3′-untranslated region; LPS, lipopolysaccharide; NC, negative control; mut, mutant; shRNA, short hairpin RNA; inb, inhibitor.

Article Snippet: Subsequently, 250 μl concentrated cell supernatant solution was obtained from the control, LPS exposure, Sp1 shRNA transfection and miR130b mimics intervention groups and assayed using the human MUC5AC ELISA assay kit (cat. no. CSB-E10109h; Cusabio Technology, LLC) to determine MU5AC concentration.

Techniques: Binding Assay, Sequencing, Expressing, Luciferase, Plasmid Preparation, Transfection, Over Expression, Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay, Reverse Transcription, Real-time Polymerase Chain Reaction, Negative Control, Mutagenesis, shRNA

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Univariate logistic regression of serum MUC5AC on clinicopathological features.

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Serum MUC5AC (mean) distribution and clinicopathological features.

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques:

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Univariate analysis for progression-free survival in neoadjuvant therapy group (n=21).

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques: Biomarker Discovery

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Multivariate analysis for neoadjuvant therapy cohort.

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques:

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Presurgery Multivariate analysis for survival.

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques:

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Comparing low and high MUC5AC groups.

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: The difference in survival between low and high serum MUC5AC groups in neoadjuvant therapy group (A, B) and FOLFIRINOX sub-group (C, D) .

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques:

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Multivariate analysis of upfront surgery population for survival (n=17).

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques:

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: The difference in progression-free survival (A) and overall survival (B) between low and high serum MUC5AC groups in upfront surgery group.

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques:

Journal: Frontiers in Oncology

Article Title: Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

doi: 10.3389/fonc.2025.1544928

Figure Lengend Snippet: Predicting recurrence using MUC5AC and CA19-9 post-surgery.

Article Snippet: Serum MUC5AC samples were analyzed using the Human MUC5AC ELISA Kit (Catalog number NBP2-76703, Novus Biologicals, Centennial, CO) following the manufacturer’s instructions.

Techniques:

Journal: International Journal of Clinical and Experimental Pathology

Article Title: miR-330 regulates interleukin-13-induced MUC5AC secretion by targeting Munc18b in human bronchial epithelial cells

doi:

Figure Lengend Snippet: Effects of IL-13 treatment on MUC5AC secretion and miR-330 expression in HBE16 cells. A: ELISA shows that MUC5AC levels increase with IL-13 concentration increasing from 0 to 60 ng/ml, with no difference at the concentration of 60 and 80 ng/ml. B: qRT-PCR shows that IL-13 suppresses miR-330 expression in a concentration-dependent manner.

Article Snippet: ELISA MUC5AC protein levels in culture supernatants were determined with Human MUC5AC ELISA kit (USCNK, Wuhan, China), according to instructions provided by the manufacturer.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Quantitative RT-PCR

Journal: International Journal of Clinical and Experimental Pathology

Article Title: miR-330 regulates interleukin-13-induced MUC5AC secretion by targeting Munc18b in human bronchial epithelial cells

doi:

Figure Lengend Snippet: Association between miR-330 expression and MUC5AC secretion induced by IL-13. A and B: qRT-PCR shows miR-330 expression in HBE16 cells transfected with miR-330 mimic, miR-330 inhibitor, or their respective controls. C and D: ELISA shows that the increase of miR-330 inhibits MUC5AC secretion induced by IL-13, while the decrease of miR-330 exacerbates IL-13-induced MUC5AC secretion. *P < 0.05, **P < 0.01 and ***P < 0.001.

Article Snippet: ELISA MUC5AC protein levels in culture supernatants were determined with Human MUC5AC ELISA kit (USCNK, Wuhan, China), according to instructions provided by the manufacturer.

Techniques: Expressing, Quantitative RT-PCR, Transfection, Enzyme-linked Immunosorbent Assay

Journal: International Journal of Clinical and Experimental Pathology

Article Title: miR-330 regulates interleukin-13-induced MUC5AC secretion by targeting Munc18b in human bronchial epithelial cells

doi:

Figure Lengend Snippet: Function of Munc18b. A-D: qRT-PCR and Western blot assay show Munc18b mRNA and protein levels in HBE16 cells transfected with si-Munc18b, pcDNA-Munc18b, or their respective controls. E and F: ELISA shows that Munc18b knockdown significantly inhibits IL-13-induced MUC5AC secretion, and Munc18b overexpression obviously aggravates MUC5AC secretion induced by IL-13. *P < 0.05 and **P < 0.01.

Article Snippet: ELISA MUC5AC protein levels in culture supernatants were determined with Human MUC5AC ELISA kit (USCNK, Wuhan, China), according to instructions provided by the manufacturer.

Techniques: Quantitative RT-PCR, Western Blot, Transfection, Enzyme-linked Immunosorbent Assay, Knockdown, Over Expression

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: Effective-Component Compatibility of Bufei Yishen Formula (ECC-BYF) III Inhibits Mucus Hypersecretion by BEAS-2B Cells via miR-146a-5p-Mediated Regulation of the EGFR/MEK/ERK Pathway

doi: 10.2147/COPD.S498477

Figure Lengend Snippet: Primers Used in This Study

Article Snippet: The cell supernatants were collected to measure TNF-α levels (E-EL-H2306, Elabscience, China), and the cells were collected to measure MUC5AC (ELK2098, ELK Biotechnology, China) and MUC5B (ELK2122, ELK Biotechnology, China) levels.

Techniques: Sequencing, Negative Control

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: Effective-Component Compatibility of Bufei Yishen Formula (ECC-BYF) III Inhibits Mucus Hypersecretion by BEAS-2B Cells via miR-146a-5p-Mediated Regulation of the EGFR/MEK/ERK Pathway

doi: 10.2147/COPD.S498477

Figure Lengend Snippet: Screening of conditions to establish a model of mucus hypersecretion by BEAS-2B cells exposed to CSE. ( A ) Effects of different durations and concentrations of CSE on the proliferation of BEAS-2B cells. ( B and C ) Microscopic images of BEAS-2B cells treated with different concentrations of CSE (0%, 2.5%, 5%, 7.5%, 10%, 15%) for different times (6 h, 12 h, 24 h, 48 h) (×10). ( D and E ) Relative mRNA expression of MUC5AC and MUC5B in BEAS-2B cells after exposure to CSE for different durations and at different concentrations. ( F ) Relative protein expression of MUC5AC in BEAS-2B cells exposed to different concentrations of CSE for 12 h, 18 h and 24 h. All the data are presented as the means ± SDs (n = 3), a P < 0.05, aa P < 0.01 versus the control group.

Article Snippet: The cell supernatants were collected to measure TNF-α levels (E-EL-H2306, Elabscience, China), and the cells were collected to measure MUC5AC (ELK2098, ELK Biotechnology, China) and MUC5B (ELK2122, ELK Biotechnology, China) levels.

Techniques: Expressing, Control

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: Effective-Component Compatibility of Bufei Yishen Formula (ECC-BYF) III Inhibits Mucus Hypersecretion by BEAS-2B Cells via miR-146a-5p-Mediated Regulation of the EGFR/MEK/ERK Pathway

doi: 10.2147/COPD.S498477

Figure Lengend Snippet: The optimal intervention concentration of ECC-BYF III was screened. ( A ) Effects of different durations and concentrations of ECC-BYF III on the proliferation of BEAS-2B cells. All the data are presented as the means ± SDs (n =3), a P < 0.05, aa P < 0.01 versus the control group. ( B and C ) Relative mRNA expression of MUC5AC and MUC5B in BEAS-2B cells exposed to 5% CSE or 10% CSE in the ECC-BYF III low-, medium- and high-dose groups. All the data are presented as the means ± SDs (n =3), a P < 0.05, aa P < 0.01 versus the control group. b P < 0.05, bb P < 0.01 versus the model group. c P < 0.05, cc P < 0.01 versus the ECC-BYF III -M group. ( D and E ) Relative protein expression of MUC5AC in BEAS-2B cells exposed to 5% CSE and 10% CSE in the ECC-BYF III low-, medium- and high-dose groups. All the data are presented as the means ± SDs (n =3), a P < 0.05, aa P < 0.01 versus the control group. b P < 0.05, bb P < 0.01 versus the model group. c P < 0.05, cc P < 0.01 versus the ECC-BYF III-L group.

Article Snippet: The cell supernatants were collected to measure TNF-α levels (E-EL-H2306, Elabscience, China), and the cells were collected to measure MUC5AC (ELK2098, ELK Biotechnology, China) and MUC5B (ELK2122, ELK Biotechnology, China) levels.

Techniques: Concentration Assay, Control, Expressing

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: Effective-Component Compatibility of Bufei Yishen Formula (ECC-BYF) III Inhibits Mucus Hypersecretion by BEAS-2B Cells via miR-146a-5p-Mediated Regulation of the EGFR/MEK/ERK Pathway

doi: 10.2147/COPD.S498477

Figure Lengend Snippet: ECC-BYF III can ameliorate mucus hypersecretion and affect the levels of inflammatory factors, miR-146a-5p and EGFR/MEK/ERK pathway components. ( A and B ) Relative protein expression of MUC5AC and MUC5B in each group. ( C ) Relative mRNA expression of IL-4, IL-1α, IL-8 and TNF-α in each group. ( D ) Relative protein expression of TNF-α in each group. ( E and F ) Relative mRNA expression of miR-146a-5p, MUC5AC and MUC5B in each group. ( G – K ) Expression of EGFR/MEK/ERK pathway-related proteins affected by ECC-BYF III. All the data are presented as the mean ± SDs (n =3), a P < 0.05, aa P < 0.01 versus the control group. b P < 0.05, bb P < 0.01 versus the model group.

Article Snippet: The cell supernatants were collected to measure TNF-α levels (E-EL-H2306, Elabscience, China), and the cells were collected to measure MUC5AC (ELK2098, ELK Biotechnology, China) and MUC5B (ELK2122, ELK Biotechnology, China) levels.

Techniques: Expressing, Control

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: Effective-Component Compatibility of Bufei Yishen Formula (ECC-BYF) III Inhibits Mucus Hypersecretion by BEAS-2B Cells via miR-146a-5p-Mediated Regulation of the EGFR/MEK/ERK Pathway

doi: 10.2147/COPD.S498477

Figure Lengend Snippet: Effects of miR-146a-5p overexpression on MUC5AC, MUC5B and the EGFR/MEK/ERK pathway. ( A and B ) The relative mRNA expression levels of miR-146a-5p, MUC5AC and MUC5B in each group after transfection. ( C ) Protein expression of MUC5AC after transfection. All the data are presented as the means ± SDs (n = 3). NC Control group compared with NC Model group, aa P < 0.01; NC Control group compared with mimic Control group, bb P < 0.01; NC Model group compared with mimic Model group, c P < 0.05, cc P < 0.01. ( D – G ) Effect of miR-146a-5p overexpression on the EGFR/MEK/ERK pathway. All the data are presented as the means ± SDs (n =3). Mimic Control group compared with NC Control group, a P < 0.05, aa P < 0.01; NC Control group compared with NC Model group, b P < 0.05, bb P < 0.01; NC Model group compared with mimic Model group, c P < 0.05, cc P < 0.01.

Article Snippet: The cell supernatants were collected to measure TNF-α levels (E-EL-H2306, Elabscience, China), and the cells were collected to measure MUC5AC (ELK2098, ELK Biotechnology, China) and MUC5B (ELK2122, ELK Biotechnology, China) levels.

Techniques: Over Expression, Expressing, Transfection, Control

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: Effective-Component Compatibility of Bufei Yishen Formula (ECC-BYF) III Inhibits Mucus Hypersecretion by BEAS-2B Cells via miR-146a-5p-Mediated Regulation of the EGFR/MEK/ERK Pathway

doi: 10.2147/COPD.S498477

Figure Lengend Snippet: Effects of miR-146a-5p downregulation on the ability of ECC-BYF III to regulate mucus hypersecretion and the EGFR/MEK/ERK pathway in BEAS-2B cells. ( A and B ) Relative mRNA expression of miR-146a-5p, MUC5AC and MUC5B in each group after transfection. ( C ) Protein expression of MUC5AC after transfection. ( D – G ) Effect of downregulating miR-146a-5p on the EGFR/MRK/ERK pathway. All the data are presented as the means ± SDs (n =3). IN NC Control group compared with IN NC Model group, aa P < 0.01; IN NC Model group compared with IN NC ECC-BYF III group, b P < 0.05, bb P < 0.01; IN NC ECC-BYF III group compared with IN ECC-BYF III group, cc P < 0.01.

Article Snippet: The cell supernatants were collected to measure TNF-α levels (E-EL-H2306, Elabscience, China), and the cells were collected to measure MUC5AC (ELK2098, ELK Biotechnology, China) and MUC5B (ELK2122, ELK Biotechnology, China) levels.

Techniques: Expressing, Transfection, Control